Genomic Profiling of HER2‐Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2‐Positive Advanced Gastric Cancer Treated with Trastuzumab

BACKGROUND. HER2‐positive gastric cancer (GC) affects 7%–34% of patients with GC. Trastuzumab‐based first‐line treatment has become the standard of care for HER2‐positive advanced gastric cancer (AGC). However, there are no clinically validated biomarkers for resistance to HER2‐targeted therapies. U...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Díaz‐Serrano, Asunción, Angulo, Barbara, Dominguez, Carolina, Pazo‐Cid, Roberto, Salud, Antonieta, Jiménez‐Fonseca, Paula, Leon, Ana, Galan, Maria Carmen, Alsina, Maria, Rivera, Fernando, Plaza, J. Carlos, Paz‐Ares, Luis, Lopez‐Rios, Fernando, Gómez‐Martín, Carlos
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192610/
https://ncbi.nlm.nih.gov/pubmed/29700210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0379
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados